

44. The method of claim 3, wherein said promoter is selected from the group consisting of an epithelial cell specific promoter, an endothelial cell specific promoter and a smooth muscle cell specific promoter.

45. The method of claim 5, wherein said promoter is selected from the group consisting of an epithelial cell specific promoter, an endothelial cell specific promoter and a smooth muscle cell specific promoter.

46. The pharmaceutical composition of claim 30, wherein said promoter is selected from the group consisting of an epithelial cell specific promoter, an endothelial cell specific promoter and a smooth muscle cell specific promoter.

47. The kit of claim 35, wherein said promoter is selected from the group consisting of an epithelial cell specific promoter, an endothelial cell specific promoter and a smooth muscle cell specific promoter.

48. The kit of claim 38, wherein said promoter is selected from the group consisting of an epithelial cell specific promoter, an endothelial cell specific promoter and a smooth muscle cell specific promoter.

49. A kit for the treatment of a human subject having airway or vascular disease comprising:

a first pharmaceutical composition comprising a vector comprising a DNA sequence encoding a β_2 AR operably linked to a promoter that is functional in at least one cell of the airways or blood vessels of a human subject, wherein said cell is selected from the group consisting of an airway epithelial cells, airway smooth muscle cells, blood vessel endothelial cells and blood vessel smooth muscle cells; and a pharmaceutically acceptable carrier;

a second pharmaceutical composition comprising at least one β_2 -adrenergic agonist and a pharmaceutically acceptable carrier; and

a third pharmaceutical composition comprising a hormone or pharmacological agent that induces said promoter to express said β_2 AR in at least one of said cells.